Opthea (ASX:OPT) touted additional data today from the Phase I/IIa trial of its wet age-related macular degeneration therapy, OPT-302.
The 50-patient Phase I/IIa trial recruited participants who were either treatment-naive or previously treated with an intravitreal anti-VEGF therapy. Researchers evaluated OPT-302 as a monotherapy and in combination with Lucentis (ranibizumab).
Get the full story at our sister site, Drug Delivery Business News.
The post Opthea touts data from wet-AMD trial appeared first on MassDevice.
from MassDevice http://ift.tt/2w9R4Qx
Cap comentari:
Publica un comentari a l'entrada